Demetrix biotech commercially manufactures rare cannabinoids that have the potential to deliver a range of health benefits using an environmentally-lighter impact than traditional agricultural methods.
Demetrix CEO Jeff Ubersax (right) and President Darren Platt at their cannabinoid research and development facility in West Berkeley.
